The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma

Rhee, Hyungjin; Park, Mi‐Suk

doi:10.3348/kjr.2019.0862

Cited by 39 publications

(26 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As many fields of cancer research have adopted the use of computer-aided diagnosis and prediction models, these are desperately needed within the clinical realm of pancreatic cancer in order to push back against this vicious disease. While these studies show promise for “phenotyping” tumors and pancreatic disease prognosis, continued research is needed to resolve the issue of unresectable pancreatic cancer prognosis [ 134 ]. While radiomics and deep learning models have shown promise for the diagnosis, prognosis, and prediction of optimal treatment of pancreatic diseases, there is a need for further and better studies.…”

Section: Limitations and Future Directionsmentioning

confidence: 99%

Using Quantitative Imaging for Personalized Medicine in Pancreatic Cancer: A Review of Radiomics and Deep Learning Applications

Preuss

Thach

Liang

et al. 2022

Cancers

View full text Add to dashboard Cite

As the most lethal major cancer, pancreatic cancer is a global healthcare challenge. Personalized medicine utilizing cutting-edge multi-omics data holds potential for major breakthroughs in tackling this critical problem. Radiomics and deep learning, two trendy quantitative imaging methods that take advantage of data science and modern medical imaging, have shown increasing promise in advancing the precision management of pancreatic cancer via diagnosing of precursor diseases, early detection, accurate diagnosis, and treatment personalization and optimization. Radiomics employs manually-crafted features, while deep learning applies computer-generated automatic features. These two methods aim to mine hidden information in medical images that is missed by conventional radiology and gain insights by systematically comparing the quantitative image information across different patients in order to characterize unique imaging phenotypes. Both methods have been studied and applied in various pancreatic cancer clinical applications. In this review, we begin with an introduction to the clinical problems and the technology. After providing technical overviews of the two methods, this review focuses on the current progress of clinical applications in precancerous lesion diagnosis, pancreatic cancer detection and diagnosis, prognosis prediction, treatment stratification, and radiogenomics. The limitations of current studies and methods are discussed, along with future directions. With better standardization and optimization of the workflow from image acquisition to analysis and with larger and especially prospective high-quality datasets, radiomics and deep learning methods could show real hope in the battle against pancreatic cancer through big data-based high-precision personalization.

show abstract

Section: Limitations and Future Directionsmentioning

confidence: 99%

Using Quantitative Imaging for Personalized Medicine in Pancreatic Cancer: A Review of Radiomics and Deep Learning Applications

Preuss

Thach

Liang

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…По данным КТ, опухоль имеет малую плотность по отношению к непораженной ткани ПЖ, часто обнаруживают атрофию остальной части ПЖ и признак "двойного протока", обусловленный отображением расширенного ППЖ и ОЖП, причем эти изменения более часто выявляют при опухолях больших размеров (>20 мм). При контрастном усилении образование резко гиподенсное по отношению к непораженной ткани ПЖ, демонстрирует слабое накопление КП на 40-50-й секунде после введения (панкреатическая фаза) и на 65-70-й секунде (венозная фаза) [52].…”

Section: обсуждение результатовunclassified

“…Это позволяет увеличить чувствительность МРТ в диагностике аденокарциномы ПЖ даже небольших размеров (<20 мм) с 75-76 до 96-98% [53,54]. При контрастном усилении опухоль демон стрирует особенности, аналогичные выявляемым при КТ [52]. МРХПГ -необходимое исследование, поскольку позволяет рассмотреть желчные протоки и ППЖ, определить уровень обструкции и расширение проксимальных протоков (рис.…”

Section: обсуждение результатовunclassified

See 1 more Smart Citation

Computer-assisted and magnetic resonance imaging assessment of tumors and tumor invasion of the duodenum

Kаrmаzаnovsky

Abuladze²

2022

Ann. hir. gepatol.

View full text Add to dashboard Cite

Aim: To present the computed tomography and magnetic resonance imaging assessments of benign and malignant duodenal tumors, pancreatic head adenocarcinoma invading the duodenum, and duodenal dystrophy.Methods: We searched for scientific papers and clinical guidelines in the information and analytical databases PubMed and Google Scholar from the 2013–2021 period using the following search terms: duodenal neoplasms, adenocarcinoma, duodenum, duodenal neuroendocrine tumors, duodenal adenoma, gastrointestinal stromal tumor, cholangiocarcinoma, radiology, magnetic resonance imaging, computed tomography, pancreatic head cancer. Then, we examined the reference lists of all the identified studies to collate the papers that would meet the eligibility criteria.Results: We analyzed 1494 articles, 22 of which were included in our review. From the papers published within 1992–2021, 35 articles from the reference lists were additionally included. Based on the search results, several domains of articles were clustered; the articles from those domains were reviewed and evaluated that involved the abovementioned diagnostic features.Conclusion: The early diagnosis and selection of appropriate management methods remain extremely relevant for the treatment of duodenal tumors, and hence, require careful attention from diagnosticians and clinicians.

show abstract

“…Pancreatic adenocarcinoma (PAC) is considered a lethal malignancy due to high mortality and morbidity, as it is the fourth leading cause of death in the USA and the fifth in Korea [ 1 , 2 , 3 ]. The most important prognostic factor is the stage at which the patient is diagnosed.…”

Section: Introductionmentioning

confidence: 99%

Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report

2021

View full text Add to dashboard Cite

Approximately 80% of pancreatic cancer is diagnosed at an advanced stage, due to lack of or vague symptoms when the cancer is still localized, leading to a high mortality rate. Known risk factors for developing pancreatic cancer are family history, obesity, type 2 diabetes, and alcohol and tobacco use. There has been a remarkable development in diagnosis modalities and molecular testing, but early detection is still infrequent. The majority of clinical trials have not shown significant efficacy in pancreatic cancer, and treatment strategy remains limited. Additional prognostic factors should be highlighted to obtain appropriate treatment options, including precision medicine, and improve survival outcomes. After the PRODIGE study in 2011 and the MPAC trial in 2013, a new drug (liposomal irinotecan; Onivyde ®) appeared in the strategy, especially after failure of gemcitabine-based treatment. In 2016, the NAPOLI-1 trial showed evidence of the efficacy of the liposomal irinotecan combination (liposomal irinotecan +5-fluorouracile + folinic acid); now, it is considered the standard treatment for relapsing patients. Since NAPOLI-1, real-world data have provided similar results. Herein, we report the story of a 61-year-old woman who was treated with liposomal irinotecan combination (nal-IRI/5-FU/LV) for 8 months with good surgical response, but treatment was discontinued due to economic burden. After the start of treatment (or 1? cycle of liposomal irinotecan treatment), the patient was in a better condition. The liver metastases had disappeared. The combination with liposomal irinotecan was re-administered with patient’s approval. Upon rechallenge with the liposomal irinotecan combination, she showed a partial response, and the treatment was given for 7 months. In this report, we tried to identify the prognostic factors leading to the efficacy of the liposomal irinotecan combination.

show abstract

The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma

Cited by 39 publications

References 120 publications

Using Quantitative Imaging for Personalized Medicine in Pancreatic Cancer: A Review of Radiomics and Deep Learning Applications

Using Quantitative Imaging for Personalized Medicine in Pancreatic Cancer: A Review of Radiomics and Deep Learning Applications

Computer-assisted and magnetic resonance imaging assessment of tumors and tumor invasion of the duodenum

Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report

Contact Info

Product

Resources

About